Rebecca A G Christensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/101895/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain postâ€bariatric surgery. Clinical Obesity, 2019, 9, e12323.	1.1	83
2	Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 427-438.	1.1	57
3	Realâ€World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. Obesity, 2019, 27, 917-924.	1.5	50
4	The association of estimated cardiorespiratory fitness with COVID-19 incidence and mortality: A cohort study. PLoS ONE, 2021, 16, e0250508.	1.1	30
5	The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. Critical Reviews in Food Science and Nutrition, 2020, 60, 1614-1630.	5.4	26
6	Weight loss and persistence with liraglutide 3.0 mg by obesity class in the realâ€world effectiveness study in Canada. Obesity Science and Practice, 2020, 6, 439-444.	1.0	17
7	Time-Restricted Eating: A Novel and Simple Dietary Intervention for Primary and Secondary Prevention of Breast Cancer and Cardiovascular Disease. Nutrients, 2021, 13, 3476.	1.7	15
8	Weight loss medications in Canada – a new frontier or a repeat of past mistakes?. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 413-417.	1.1	9
9	Measures of Adiposity and Risk of Testing Positive for SARS-CoV-2 in the UK Biobank Study. Journal of Obesity, 2021, 2021, 1-6.	1.1	9
10	The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review. Journal of Drug Assessment, 2019, 8, 184-191.	1.1	5
11	Predictors of Weight Loss and Weight Gain in Weight Management Patients during the COVID-19 Pandemic. Journal of Obesity, 2021, 2021, 1-8.	1.1	5
12	Absolute Weight Loss, and Not Weight Loss Rate, Is Associated with Better Improvements in Metabolic Health. Journal of Obesity, 2019, 2019, 1-6.	1.1	4
13	Realâ€world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program. Obesity Science and Practice, 2020, 6, 382-389.	1.0	4
14	Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. International Journal of Obesity, 2021, 45, 1687-1695.	1.6	4
15	Sequential diets and weight loss: Including a low-carbohydrate high-fat diet with and without time-restricted feeding. Nutrition, 2021, 91-92, 111393.	1.1	2
16	Using real-world transaction data to identify money laundering: Leveraging traditional regression and machine learning techniques. STEM Fellowship Journal, 0, , 1-11.	0.5	2
17	Effectiveness of a Communityâ€Based Weight Management Program for Patients Taking Antidepressants and/or Antipsychotics. Obesity, 2019, 27, 1539-1544.	1.5	1
18	The association of sex and calendar month with changes in weight: A retrospective cohort study of a community-based weight management clinic. Obesity Research and Clinical Practice, 2021, 15, 515-517.	0.8	1

#	Article	IF	CITATIONS
19	Response to "Liraglutide Effectiveness: Is There a Realâ€World Clinical Benefit?â€: Obesity, 2019, 27, 1728-1728.	1.5	0
20	Four Dates, One Future. University of Toronto Journal of Public Health, 2020, 1, .	0.0	0